Modelling CD4 T Cell Recovery in Hepatitis C and HIV Co-infected Children Receiving Antiretroviral Therapy

Adedeji O. Majekodunmi, MB BS, MRes,† Claire Thorne, PhD,§ Ruslan Malayuta, MD,¶ Alla Volokha, PhD,¶ Robin E. Callard, PhD,† Nigel J. Klein, MB BS, PhD,† and Joanna Lewis, PhD,|| on behalf of The European Paediatric HIV/HCV Co-infection Study group in the European Pregnancy and Paediatric HIV Cohort Collaboration and the Ukraine Paediatric HIV Cohort Study in EuroCoord

Background: The effect of hepatitis C virus (HCV) coinfection on CD4+ T cell recovery in treated HIV-infected children is poorly understood.

Objective: To compare CD4+ T cell recovery in HIV/HCV coinfected children with recovery in HIV monoinfected children.

Method: We studied 355 HIV monoinfected and 46 HIV/HCV coinfected children receiving antiretroviral therapy (ART) during a median follow-up period of 4.2 years (interquartile range: 2.7–5.3 years). Our dataset came from the Ukrainian Pediatric HIV Cohort and the HCV/HIV coinfection study within the European Pregnancy and Paediatric HIV Cohort Collaboration. We fitted an asymptotic nonlinear mixed-effects model of CD4+ T cell reconstitution to age-standardized CD4 counts in all 401 children and investigated factors predicting the speed and extent of recovery.

Results: We found no significant impact of HCV coinfection on either pre-ART or long-term age-adjusted CD4 counts (z scores). However, the rate of increase in CD4 z score was slower in HIV/HCV coinfected children when compared with their monoinfected counterparts ($P < 0.001$). Both monoinfected and coinfected children starting ART at younger ages had higher pre-ART ($P < 0.001$) and long-term ($P < 0.001$) CD4 z scores than those who started when they were older.

Conclusions: HIV/HCV coinfected children receiving ART had slower CD4+ T cell recovery than HIV monoinfected children. HIV/HCV coinfection had no impact on pre-ART or long-term CD4 z scores. Early treatment of HIV/HCV coinfected children with ART should be encouraged.

Key Words: pediatric hepatitis C, HIV and hepatitis C coinfection, CD4+ T cell reconstitution, nonlinear mixed-effects modeling, antiretroviral therapy

(Pediatr Infect Dis J 2017;36:e123–e129)

Globally, over 170 million individuals are estimated to be living with chronic hepatitis C virus (HCV) infection.1 Of these, an estimated 11 million are children under the age of 15.2 The prevalence of pediatric HCV infection varies geographically, from 0.05% in the Western world to 5.8% in resource-limited settings.3 As a result of shared routes of transmission, about a third of the 37 million HIV-infected individuals worldwide are thought to be coinfected with HCV.4,5

Most children with HCV are vertically infected, and an estimated 60,000 HCV-infected infants are born worldwide every year.4 A recent meta-analysis estimated the risk of mother-to-child transmission to be 6% for HCV-seropositive, RNA-positive women, increasing to nearly 11% for those with HCV coinfection.2 Although highly debated and only demonstrated in a few studies, additional factors contributing to increased risk of transmission may include high hepatitis C viral load and the presence of HCV in maternal peripheral blood mononuclear cells.4,6,7 HIV/HCV coinfected mothers receiving combination antiretroviral therapy (ART) are less likely to transmit HCV to their unborn child.8 The incidence of spontaneous HCV clearance varies in childhood depending on virus genotype and figures from 7.5% to 25% have been quoted in the literature.10–12

In this study, we aimed to improve understanding of the impact of HCV coinfection on CD4+ T cell recovery in children receiving ART. By using a larger study population than has
Data Sources and Eligibility

Data on coinfection children came from a study of HIV/HCV coinfection within the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC), in 8 countries across Europe, including Ukraine. In the EPPICC HIV/HCV coinfection study, children older than 18 months of age, adolescents and young adults younger than 25 years of age were eligible for inclusion if they were infected with HIV and with chronic HCV acquired vertically or in childhood.

Data on monoinfected children came from the Ukraine Paediatric HIV Cohort Study. The Ukraine Paediatric HIV Cohort Study was established in January 2011 and enrolled HIV-infected infants, children and adolescents being cared for in 6 HIV/AIDS centers in Ukraine. This study collected anonymized demographic, clinical and laboratory data on children according to a standard protocol, with informed consent and is a member of EPPICC. The included studies were observational, with laboratory testing being conducted locally. Children with known spontaneous viral clearance of HCV (ie, disappearance of HCV RNA in ≥2 consecutive serum samples taken 6 months apart) were excluded.

Definitions

All children were older than 18 months of age. HCV-infected children were identified by detection of positive HCV antibody and/or equal to 2 positive HCV RNA detected on 2 separate clinic visits at least 3 months apart. HIV infection in children was defined as detection of HIV antibody and/or positive HIV RNA or DNA polymerase chain reaction in a minimum of 2 samples obtained on separate visits. “Coinfected children” in this study refers to HIV/HCV coinfected children, while “monoinfected children” refers to HIV monoinfected children. Our threshold for detection of HIV viral load was set at 50 copies/mL.

Ethical Approval

Each participating cohort in EPPICC followed local ethical guidelines. The Ukraine Paediatric HIV Cohort Study has approval from the UCL Research Ethics Committee and local institutional review boards.

Age-adjustment of CD4 Counts

Healthy children demonstrate a pronounced fall in their CD4+ T cell count as they approach adulthood.36 Because of these age-associated changes, a direct comparison of raw CD4 counts between children of different age groups is not possible. In view of this, raw CD4 counts of our cohort were converted to age-standardized z scores. These z scores were originally calculated based on the normalized expected distribution for age-matched HIV-negative children born to HIV-positive mothers.31 A z score of 0 implies that a child has a normal CD4 count for their age, while scores of ±2 indicate that a child is on the 97.7% and 2.3% centiles, respectively, of the expected CD4 count for their age. Although CD4 percentage is relatively stable with age and has been widely used in published studies, we have chosen to use age-corrected CD4 counts in our analysis because CD4 percentage is influenced by CD8 T cells which are likely to be affected by HIV/HCV coinfection. Furthermore, CD4 counts have been shown to be of no less prognostic value than CD4 percentage.32 Children with fewer than 2 CD4 measurements were excluded from the study.

Mixed-effects Modeling

CD4 z scores were analyzed using nonlinear mixed-effects models. Within the mixed-effects framework, we assumed that recovery of the CD4 z score followed an asymptotic pattern as described elsewhere37 and illustrated in Figure 1. Briefly, in this model, the z score starts at a below-healthy initial value, int. Following ART initiation, the z score increases, trending in the long term to a higher, stable level, asy, as described by the following equation:

\[
    z_i = \text{asy} - \left( \text{asy} - \text{int} \right) e^{-ct} + \varepsilon_i
\]

where \(z_i\) represents CD4 z score for child \(i\) at time \(t_i\) after starting ART; \(\text{int}\) represents CD4 z score at ART initiation for child \(i\); \(\text{asy}\) represents the long-term CD4 z score for child \(i\); \(c\) is a parameter that describes the rate of increase in CD4 z score for child \(i\); \(\ln(2)/c\), being the time taken to achieve half of the total recovery from \(\text{int}\) to \(\text{asy}\). The term \(\varepsilon_i\) is the “residual error,” which represents measurement error, random variation and model misspecification leading to differences between the recorded data and the form of the curve in Figure 1. In previous studies, this approach has provided a good description of CD4+ T cell dynamics in children starting ART,33,34 with all 3 of the model parameters conveying a clear clinical meaning (Appendix, Supplemental Digital Content 1, http://links.lww.com/INF/C639).

Covariate Analysis

We used forward and backward stepwise selection with exit \(P\) values of 0.05 and 0.01, respectively (likelihood ratio test), to investigate potential effects on CD4 recovery of: age and AIDS status at start of ART, gender, HCV status, pre-ART HIV viral load and EPPICC cohort.

Software and Algorithms

All mixed-effects model fitting was by maximum likelihood implemented in NONMEM.35,36 Further data analysis was done in R (R Foundation for Statistical Computing, Vienna, Austria)37 and predictions generated from the model were plotted in Wolfram Mathematica.38

RESULTS

Characteristics of the study population are described in Table 1. A total of 355 HIV monoinfected and 46 coinfected children

FIGURE 1. A schematic showing the mathematical model of immune reconstitution used in this study. C is the rate of recovery of age-adjusted CD4 counts. After ART, patients are expected to reconstitute their CD4+ T cells from an initial age-adjusted count (int) to a steady value (asy).
TABLE 1. Characteristics of Study Population

| Demographics                              | HIV Monoinfected | HIV/HCV Coinfected |
|-------------------------------------------|------------------|--------------------|
| Number of children                        | 355              | 46                 |
| Gender, n (%)                             |                  |                    |
| Male                                      | 171 (48.2)       | 20 (43.5)          |
| Female                                    | 184 (51.8)       | 25 (54.3)          |
| Unknown                                   | —                | 1 (2.2)            |
| Age at start of ART (yr)                  |                  |                    |
| Median age                                | 4.40             | 3.12               |
| Mean age                                  | 4.90             | 3.81               |
| HIV transmission route, n (%)             |                  |                    |
| Vertical                                  | 349 (98.3)       | 45 (97.8)          |
| Transfusion                               | 3 (0.85)         |                    |
| Unknown                                   | 3 (0.85)         | 1 (2.2)            |
| HCV transmission route, n (%)             |                  |                    |
| Vertical                                  | —                | 40 (87)            |
| Unknown                                   | —                | 6 (13)             |
| AIDS status, n (%)                        |                  |                    |
| Yes                                       | 145 (42.4)       | 6 (13)             |
| No                                        | 197 (57.6)       | 39 (84.8)          |
| Unknown                                   | —                | 1 (2.2)            |
| Pre-ART HIV viral load                    |                  |                    |
| <50 copies/mL, n (%)                      | 11 (3.1)         |                    |
| ≥50 copies/mL, n (%)                      | 203 (57.2)       | 24 (52.2)          |
| Unknown, n (%)                            | 141 (39.7)       | 22 (47.8)          |
| Median log viral load at most recent visit, n (%) | 10.6 (7.49–12.93) | 12.8 (11.65–13.61) |

Medicare of CD4 z scores when compared with older children.

Factors Determining Pre-ART and Long-term CD4 Z Score

We found that on average (fixed effects), children started ART with a CD4 z score of −2.42, corresponding to the 0.78th centile in uninfected children of the same age. Pre-ART z score was 0.32 units lower per year older at ART initiation, and there was also an effect of cohort, with children from the United Kingdom and Italy starting ART with lower CD4 counts for their age and the children in the Spanish cohort starting with higher CD4 z scores (complete effect sizes are provided in Table 2). The only predictor of lower long-term CD4 level for age was the age at ART initiation: long-term z score was 0.11 units lower per year older at ART initiation. The average long-term z score from the final model was −1.07, which corresponds to the 14th centile.

Figure 3A shows model predictions (fixed effects) for 3 categories of HIV monoinfected children at 2, 4, and 8 years. As expected, younger monoinfected children commence ART at higher age-adjusted CD4 counts and achieve higher long-term values of CD4 z scores when compared with older children.

Hepatitis C Coinfected Children Have a Slower Rate of Increase in CD4 Z Score Than HIV Monoinfected Children

HCV coinfection was a significant predictor of the rate of CD4 z score recovery (denoted c in Equation 1). We found that coinfected children had a significantly reduced recovery rate of 0.357 per year compared to 0.78 per year in monoinfected children (Fig. 2B). This difference corresponds to a time for half the long-term recovery to occur of 2 years in coinfected children, compared with 5 months (0.45 years) in monoinfected children. Interestingly, we found no statistically significant effect of HCV coinfection on either pre-ART or long-term CD4 z scores (P = 0.80 or P = 0.77, respectively), suggesting that although recovery was slower in coinfected children, they started ART with similar CD4 counts, and on long-term therapy do eventually achieve similar CD4 levels to their monoinfected peers.

Pre-ART HIV Viral Load Had No Impact on Immune Recovery

To investigate the effect of pre-ART viral load on CD4 recovery, we analyzed a subset of our data consisting of 238 children with undetectable HIV viral load were on ART for a median of 3.1 years (IQR: 2.6–7.5 years). The only predictor of lower long-term CD4 level for age was the age at ART initiation: long-term z score was 0.11 units lower per year older at ART initiation. The average long-term z score from the final model was −1.07, which corresponds to the 14th centile.

Figure 3A shows model predictions (fixed effects) for 3 categories of HIV monoinfected children at 2, 4, and 8 years. As expected, younger monoinfected children commence ART at higher age-adjusted CD4 counts and achieve higher long-term values of CD4 z scores when compared with older children.

Hepatitis C Coinfected Children Have a Slower Rate of Increase in CD4 Z Score Than HIV Monoinfected Children

HCV coinfection was a significant predictor of the rate of CD4 z score recovery (denoted c in Equation 1). We found that coinfected children had a significantly reduced recovery rate of 0.357 per year compared to 0.78 per year in monoinfected children (Fig. 2B). This difference corresponds to a time for half the long-term recovery to occur of 2 years in coinfected children, compared with 5 months (0.45 years) in monoinfected children. Interestingly, we found no statistically significant effect of HCV coinfection on either pre-ART or long-term CD4 z scores (P = 0.80 or P = 0.77, respectively), suggesting that although recovery was slower in coinfected children, they started ART with similar CD4 counts, and on long-term therapy do eventually achieve similar CD4 levels to their monoinfected peers.

Pre-ART HIV Viral Load Had No Impact on Immune Recovery

To investigate the effect of pre-ART viral load on CD4 recovery, we analyzed a subset of our data consisting of 238 children with undetectable HIV viral load were on ART for a median of 3.1 years (IQR: 2.6–7.5 years). The only predictor of lower long-term CD4 level for age was the age at ART initiation: long-term z score was 0.11 units lower per year older at ART initiation. The average long-term z score from the final model was −1.07, which corresponds to the 14th centile.

Figure 3A shows model predictions (fixed effects) for 3 categories of HIV monoinfected children at 2, 4, and 8 years. As expected, younger monoinfected children commence ART at higher age-adjusted CD4 counts and achieve higher long-term values of CD4 z scores when compared with older children.

Hepatitis C Coinfected Children Have a Slower Rate of Increase in CD4 Z Score Than HIV Monoinfected Children

HCV coinfection was a significant predictor of the rate of CD4 z score recovery (denoted c in Equation 1). We found that coinfected children had a significantly reduced recovery rate of 0.357 per year compared to 0.78 per year in monoinfected children (Fig. 2B). This difference corresponds to a time for half the long-term recovery to occur of 2 years in coinfected children, compared with 5 months (0.45 years) in monoinfected children. Interestingly, we found no statistically significant effect of HCV coinfection on either pre-ART or long-term CD4 z scores (P = 0.80 or P = 0.77, respectively), suggesting that although recovery was slower in coinfected children, they started ART with similar CD4 counts, and on long-term therapy do eventually achieve similar CD4 levels to their monoinfected peers.

Pre-ART HIV Viral Load Had No Impact on Immune Recovery

To investigate the effect of pre-ART viral load on CD4 recovery, we analyzed a subset of our data consisting of 238 children with undetectable HIV viral load were on ART for a median of 3.1 years (IQR: 2.6–7.5 years). The only predictor of lower long-term CD4 level for age was the age at ART initiation: long-term z score was 0.11 units lower per year older at ART initiation. The average long-term z score from the final model was −1.07, which corresponds to the 14th centile.

Figure 3A shows model predictions (fixed effects) for 3 categories of HIV monoinfected children at 2, 4, and 8 years. As expected, younger monoinfected children commence ART at higher age-adjusted CD4 counts and achieve higher long-term values of CD4 z scores when compared with older children.

Hepatitis C Coinfected Children Have a Slower Rate of Increase in CD4 Z Score Than HIV Monoinfected Children

HCV coinfection was a significant predictor of the rate of CD4 z score recovery (denoted c in Equation 1). We found that coinfected children had a significantly reduced recovery rate of 0.357 per year compared to 0.78 per year in monoinfected children (Fig. 2B). This difference corresponds to a time for half the long-term recovery to occur of 2 years in coinfected children, compared with 5 months (0.45 years) in monoinfected children. Interestingly, we found no statistically significant effect of HCV coinfection on either pre-ART or long-term CD4 z scores (P = 0.80 or P = 0.77, respectively), suggesting that although recovery was slower in coinfected children, they started ART with similar CD4 counts, and on long-term therapy do eventually achieve similar CD4 levels to their monoinfected peers.

Pre-ART HIV Viral Load Had No Impact on Immune Recovery

To investigate the effect of pre-ART viral load on CD4 recovery, we analyzed a subset of our data consisting of 238 children with undetectable HIV viral load were on ART for a median of 3.1 years (IQR: 2.6–7.5 years). The only predictor of lower long-term CD4 level for age was the age at ART initiation: long-term z score was 0.11 units lower per year older at ART initiation. The average long-term z score from the final model was −1.07, which corresponds to the 14th centile.

Figure 3A shows model predictions (fixed effects) for 3 categories of HIV monoinfected children at 2, 4, and 8 years. As expected, younger monoinfected children commence ART at higher age-adjusted CD4 counts and achieve higher long-term values of CD4 z scores when compared with older children.

Hepatitis C Coinfected Children Have a Slower Rate of Increase in CD4 Z Score Than HIV Monoinfected Children

HCV coinfection was a significant predictor of the rate of CD4 z score recovery (denoted c in Equation 1). We found that coinfected children had a significantly reduced recovery rate of 0.357 per year compared to 0.78 per year in monoinfected children (Fig. 2B). This difference corresponds to a time for half the long-term recovery to occur of 2 years in coinfected children, compared with 5 months (0.45 years) in monoinfected children. Interestingly, we found no statistically significant effect of HCV coinfection on either pre-ART or long-term CD4 z scores (P = 0.80 or P = 0.77, respectively), suggesting that although recovery was slower in coinfected children, they started ART with similar CD4 counts, and on long-term therapy do eventually achieve similar CD4 levels to their monoinfected peers.
who had pre-ART HIV viral load data. We compared the covariate model selection process with pre-ART HIV viral load excluded or included in addition to the other 5 covariates (age, AIDS status at start of therapy, gender, HCV status and EPPICC cohort). Both model selection processes retained only covariate relationships between asymptote, intercept and age at start of ART. There was thus no evidence that pre-ART HIV viral load predicts either long-term CD4 z scores or rate of recovery ($c$) once other factors have been taken into account, although this may be a limitation of the data available.

**DISCUSSION**

In this study, we investigated the impact of HCV coinfection on CD4+ T cell reconstitution in HIV-infected children receiving ART. By fitting a nonlinear mixed-effects model to longitudinal data from 401 children, we found that HIV/HCV coinfected children had significantly slower recovery of their age-adjusted CD4 counts than HIV monoinfected children. Despite this reduced rate of recovery, the coinfected children still managed to achieve long-term CD4+ T cell levels comparable to HIV monoinfected children. Our fixed effect estimates for rate of recovery ($c$), pre-ART and long-term CD4 z scores are consistent with others obtained in a different multicenter European pediatric study.33

In a recent paper by Marcus et al,39 it was shown that HIV/HCV coinfected adults have delayed CD4+ T cell reconstitution on ART, relative to their monoinfected counterparts. Similarly, a meta-analysis conducted by Tsiara et al40 in 2013 of 21 studies involving 22,533 adult patients reported that even though HCV had a demonstrable adverse effect on immune reconstitution in the first 2 years of ART, this trend was not sustained in the long term. Our findings in children (Fig. 3B) add to this by suggesting that this transient adverse effect of HCV coinfection in adults might be explained by a reduced rate of increase in CD4+ T cell recovery.

To the best of our knowledge, this is the first large-scale mathematical modeling analysis of the effect of HCV on CD4+ T cell recovery in HIV/HCV coinfected children. Our findings are consistent with those of Micheloud et al,41 whose smaller 2007 study found similar long-term CD4+ T cell recovery in 19 coinfected and 25 monoinfected children.

A number of mechanisms could be driving the slower rate of reconstitution in HCV coinfected children receiving ART. One possible explanation is reduced thymic output. Some
TABLE 2. Parameter Estimates for the Final Multivariate Model

| Fixed Effect | Estimate ± SE | P       | Variance of REs |
|--------------|---------------|---------|-----------------|
| Intercept    | -2.42 ± 0.28  | —       | 4.78            |
| int:age      | -0.29 ± 0.09  | <0.0001 | —               |
| Int:Poland   | 0.44 ± 0.29   | —       | —               |
| Int:Russia   | 0.69 ± 0.57   | —       | —               |
| Int:Switzerland | 0.02 ± 0.77  | —       | —               |
| Int:United Kingdom | -17.5 ± 0.93  | —       | —               |
| Int:Spain    | 2.89 ± 0.71   | —       | —               |
| Int:Germany  | 0.34 ± 0.29   | —       | —               |
| Int:Italy    | -3.63 ± 1.50  | —       | —               |
| c            | 1.55 ± 0.63   | —       | 0.39            |
| C:Coinf      | -0.77 ± 0.09  | <0.001  | —               |
| Residual error | 1.43 ± 0.16   | —       | —               |

The reference case is a Ukrainian child starting ART 4.3 years of age (median age in the dataset). Age represents age at start of ART. “int:age” represents the covariate interaction between age at start of ART and pre-ART CD4 z score. Coinf indicates HIV/HCV coinfected; RE, random effect; SE, standard errors of estimates.

A limitation of the study lies in the fact that all the HIV monoinfected children were from Ukraine, whereas the HIV/HCV coinfected children were selected from 8 countries across Europe (including Ukraine). Hence, laboratory testing was conducted locally. To take account of this, we have added the effect of cohort as a covariate in informing model predictions. An additional limitation was that the effect of pre-ART HIV viral load could be investigated only in the subset of the children in whom it was available (238 children, 59%). Nonetheless, there was no evidence of an effect of pre-ART HIV viral load on CD4+ T cell recovery. Furthermore, not all the latest HIV viral loads were measured after the same duration of ART. This is likely to account for the greater proportion of coinfected children with viral suppression. Finally, we were unable to explore the impact of HCV treatment on CD4+ T cell reconstitution because of the small number of children treated.
The findings in this study support earlier work demonstrating the importance of age on CD4+ T cell reconstitution. While our study did not find evidence of any long-term effect of HIV/HCV co-infection on CD4+ T cell recovery, the slower rate of recovery does suggest that HIV/HCV coinfection may have other, as yet unidentified, immunologic consequences. Further studies of vertically HIV/HCV coinfected children are, therefore, needed to fully understand the implications of HCV coinfection on immune recovery. Additional studies on the efficacy of the new direct-acting antivirals are needed to fully understand whether our findings will persist after their introduction in children.

ACKNOWLEDGMENTS

We are very grateful to the children and the families who contributed to the study.

The HIV/HCV Co-infection Study Group in EPPICC—participating cohorts: Belgium: Hospital St Pierre Cohort, Brussels: T. Goetghobeir, M. Hainaut, E. Van Der Kelen; Germany: German Competence Network on HIV infected children: C. Koenigs, K. Mantsch; Italy: Italian Register for HIV-infection in Children: M. de Martino, L. Galli, E. Venturini (Florence), participating sites: Dr. V. Giacomini (Milan), Dr. L. Nicolini, Dr. Del Puente (Genoa), Dr. C. Gabbiani (Turin), Dr. A. Guarini (Naples), Dr. S. Martinuzzi (Brescia), Dr. A. Minciati (Bologna); Poland: Medical University Warsaw/Regional Hospital of Infectious Disease cohort: Dr. S. Dobz, Prof. M. Marczyńska; Romania: “Victor Babes” Hospital Cohort, Romania: Dr. L. Ene, Dr. D. Duciuculescu; Russia: Republican Hospital of Infectious Diseases (RHIID), St Petersburg cohort: Dr. M. Miloenko, Dr. K. Dodonov, Dr. I. Latysheva, Prof. E. Voronin, Spain: Cohort of the Spanish Paediatric HIV Network (CoRISpe) (Madrid and Barcelona): Dr. P. Rojo, Dr. A. Noguera-Julian; Switzerland: Swiss Mother and Child HIV Cohort Study (MoCHIV): Dr. C. Rudin, Dr. A. Duppenenthal; United Kingdom: UK Collaborative HIV Paediatric Study (CHIPS): Dr. A. Turkova, Dr. A. Jadd; Ukraine: Ukraine Cohort of HIV-infected children: Dr. R. Malutya, Dr. A. Volokha, Dr. C. Thorne; The Ukraine Paediatric HIV Cohort Study in EuroCoord: Dr. T. Kaleyeva, Dr. Y. Baryshnikova (Odessa Regional Centre for HIV/AIDS), Dr. S. Soloha (Donetsk Regional Centre for HIV/AIDS), Dr. N. Bashkatova (Mariupol AIDS Center), Dr. I. Raas (Kiev City Centre for HIV/AIDS), Dr. O. Glutschenko, Dr. Z. Ruban (Mykolav Regional Centre for HIV/AIDS), Dr. N. Prymak (Kryvyi Rih) and Dr. G. Kiseleva (Simferopol).

EuroCoord Executive Board: Fiona Burns, University College London, United Kingdom; Geneviève Chêne, University of Bordeaux, France; Dominique Costagliola (Scientific Coordinator), Institut National de la Santé et de la Recherche Médicale, France; Carlo Giaquinto, Fondazione PENTA, Italy; Jesper Grarp, Region Hovedstaden, Denmark; Ole Kirk, Region Hovedstaden, Denmark; Laurence Meyer, Institut National de la Santé et de la Recherche Médicale, France; Heather Bailey, University College London, United Kingdom; Alain Volny Anne, European AIDS Treatment Group, France; Alex Panteleev, St. Petersburg City AIDS Centre, Russian Federation; Andrew Phillips, University College London, United Kingdom; Kholoud Porter, University College London, United Kingdom; Claire Thorne, University College London, United Kingdom; Dmitry Zakhmanova, St. Petersburg City AIDS Centre, Russian Federation; Jürgen Rockstroh, University of Bonn, Germany; Magda Rosinska, National Institute of Public Health, National Institute of Hygiene, Poland; Manjinder Sandhu, Genome Research Limited; Jürgen Rockstroh, University of Bonn, Germany; Magda Rosinska, National Institute of Public Health, National Institute of Hygiene, Poland; Manjinder Sandhu, Genome Research Limited; Claire Thorne, University College London, United Kingdom; Giota Toulooumi, National and Kap-Aristian University of Athens, Greece; Alain Volny Anne, European AIDS Treatment Group, France.

REFERENCES

1. World Health Organisation. Hepatitis C. 2015. Available at: http://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2016/en/. Accessed January 25, 2017.
2. Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(suppl 1):S45–S57.
3. England K, Thorne C, Newell ML. Vertically acquired paediatric coinfection with HIV and hepatitis C virus. Lancet Infect Dis. 2006;6:83–90.
4. World Health Organisation. HIV/AIDS. 2015. Available at: http://www.who.int/hiv/en/. Accessed November 03, 2015.
5. After MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44(suppl 1):S6–S9.
6. Bortolotti F, Resti M, Giaccichino R, et al. Changing epidemiologic pattern of chronic hepatitis C virus infection in Italian children. J Pediatr. 1998;133:378–381.
7. Benova L, Mohamoud YA, Calvert C, et al. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis. 2014;59:765–773.
8. Indolfi G, Azzari C, Resti M. Perinatal transmission of hepatitis C virus. J Pediatr. 2013;163:1549–1552.e1.
9. Conte D, Fraquelli M, Prati D, et al. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology. 2000;31:751–755.
10. Bortolotti F, Verucchi G, Cammà C, et al. Italian Observatory for HCV Infection and Hepatitis C in Children. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology. 2008;134:1900–1907.
11. Yeung LT, To T, King SM, et al. Spontaneous clearance of childhood hepatitis C virus infection. J Viral Hepat. 2007;14:797–805.
12. European Paediatric Hepatitis C Virus Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis. 2005;41:45–51.
13. Indolfi G, Bartolini E, Serranti D, et al. Hepatitis C in children coinfected with human immunodeficiency virus. J Pediatr Gastroenterol Nutr. 2015;61:393–399.
14. Villano SA, Vlahov D, Nelson KE, et al. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology. 1999;29:908–914.

© 2016 The Author(s). Published by Wolters Kluwer Health, Inc.
21. Fuping G, Wei L, Yang H, et al. Impact of hepatitis C virus coinfection on apoptosis of CD4+ T-cells in HIV-infected patients receiving HAART. *AIDS*. 2014;28:2381–2388.

22. Fuping G, Wei L, Yang H, et al. Impact of hepatitis C virus coinfection on HAART in HIV-infected individuals: multicentric observation cohort. *J Acquir Immune Defic Syndr*. 2010;54:137–142.

23. Peters L, Mocroft A, Soriano V, et al; EuroSIDA Study Group. Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression. *J Acquir Immune Defic Syndr*. 2009;50:457–463.

24. Steinmann GG, Klaus B, Müller-Hermelink HK. The involution of the age-related reference ranges: significance tests for centiles and confidence intervals for centiles. *Stat Med*. 2009;28:379–390.

25. Douek DC, Koup RA, McFarland RD, et al. Effect of HIV on thymic function before and after antiretroviral therapy in children. *J Infect Dis*. 2000;181:1479–1482.

26. Ometto L, De Forni D, Patiri F, et al. Immune reconstitution in HIV-1-infected children on antiretroviral therapy: role of thymic output and viral fitness. *AIDS*. 2002;16:839–849.

27. Sandgaard KS, Lewis J, Adams S, et al. Antiretroviral therapy increases thymic output in children with HIV. *AIDS*. 2013;28:209–214.

28. Gibb DM. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. *Lancet*. 2013;381:1391–1403.

29. Paediatric European Network for Treatment of AIDS. Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated the PENTA S randomised trial. *Lancet*. 2002;359:733–740.

30. Huistraat F, Haiten I, Deneyes V, et al. Age-related changes in human blood lymphocyte subpopulations. II. Varying kinetics of percentage and absolute count measurements. *Clin Immunol Immunopathol*. 1994;70:152–158.

31. Wade AM, Ades AE. Age-related reference ranges: significance tests for models and confidence intervals for centiles. *Stat Med*. 1994;13:2359–2367.